30 closest matches · ranked by relevance
Anatomic Stage IV Breast Cancer AJCC v8 · Estrogen Receptor Positive · HER2/Neu Negative
Primary: Response Rate — 29; 6 Participants
Breast Cancer · Bone Metastases
Primary: Time to Progression — 317 Days
Breast Cancer · Lung Cancer · Metastatic Cancer
Primary: Time to Development of a Malignant Skeletal-related Events (SRE) — 29.9; 27.4 months — p=0.844
Breast Cancer
Primary: Disease Free Survival. — 81.0; 79.6 percentage of patients
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8 · Metastatic Breast Carcinoma · Metastatic Malignant Neoplasm in the Bone
Primary: Progression-free Survival (Phase II) — 23.0; 19.5 months — p=0.36
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Breast Cancer
Primary: Response of Bone Marrow Micrometastases — -4.5 DTCs/mL
Breast Cancer With Bone Metastasis
Primary: Annual Overall Skeletal Morbidity Rate (SMR) — 0.26; 0.22 Number of Skeletal Events per Year
First or Second Line HER2-negative Breast Cancer · Metastatic Disease Without Bone Metastasis
Primary: Number of Participants With Progression Free Survival (PFS) — 9; 19; 6; 10 Participants
Breast Cancer
Primary: Number of Participants With Disease Control Rate at 9 Months — 35 Participants
Non Small Cell Lung Cancer With Bone Metastatses
Primary: Number of Symptomatic Skeletal Events (SSE) in Patients Receiving Xofigo With NSCLC and Bone Metastases — 1 Number of participants experiencing SSE
Breast Neoplasms
Primary: Symptomatic Skeletal Event-free Survival (SSE-FS) — 21.1; 19.9 Months — p=0.4843
Breast Cancer · Metastatic Cancer
Primary: Progression-free Survival — 10.3; 15.3 weeks
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Breast Cancer
Primary: Disease-free Survival — 88; 88; 87 percentage of analyzed participants — p=0.49
Breast Cancer · Metastatic Bone Disease
Primary: Percentage Change From Baseline in Urinary N-telopeptide of Type I Collagen (u-NTx) at Week 4 — -73; -77 Percentage change
Breast Cancer · Bone Metastases
Primary: Objective Response in Bone From Time of Initiation of Therapy to > 6 Months — 8; 7 Participants
Malignant Neoplasm · Metastatic Malignant Neoplasm in the Bone · Pain
Primary: Re-Treatment Rates - Arm 1 (8 Gy x 1) vs. Arm 2 (8 Gy x 2) — 3; 3; 19; 17 Participants — p=0.8325
Breast Cancer
Primary: Bone Scan Response Rate — 38.5 percentage of participants
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Metastatic Beast Cancer
Primary: Progression-free Survival (PFS) Rate at 3 Months — 50.1 percent of participants
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Breast Cancer
Primary: Percent Change in Lumbar Spine (L2-L4) BMD After 12 Months of Letrozole Therapy — 2.680; -3.314 Percent Change
Metastatic Breast Cancer
Primary: Number of Participants With and Without Progression Free Survival (PFS) Events — 92; 30 Participants
Breast Cancer · Brain Tumor - Metastatic
Primary: CNS Objective Response Rate (ORR) — 5; 14; 0 percentage of participants
Breast Cancer · Breast Neoplasms · Cancer of the Breast
Primary: Time to Disease Progression (Initial Treatment) — 9.28; 8.88 months — p=0.385
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Primary: Overall Survival (OS) — 34.6; 56.2 months — p=0.042
Breast Cancer
Primary: Overall Response Rate (ORR) — 35.6; 13.2 percentage of participants — p=0.42
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Breast Adenocarcinoma · DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma
Primary: Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization — 67.6; 67.9 percentage of participants — p=<=.05